# EDGAR Filing Document

**Accession Number:** 0001053691
**File Stem:** 0001437749-25-032184
**Filing Date:** 2025-10
**Character Count:** 15770
**Document Hash:** daf5a4e3340c77f5626a7608a02e3947
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-032184.hdr.sgml**: 20251029

**ACCESSION NUMBER**: 0001437749-25-032184

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251027

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251029

**DATE AS OF CHANGE**: 20251029

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CervoMed Inc.
- **CENTRAL INDEX KEY:** 0001053691
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 300645032
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37942
- **FILM NUMBER:** 251429992

**BUSINESS ADDRESS:**
- **STREET 1:** 20 PARK PLAZA
- **STREET 2:** SUITE 424
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** (617) 744-4400

**MAIL ADDRESS:**
- **STREET 1:** 20 PARK PLAZA
- **STREET 2:** SUITE 424
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Diffusion Pharmaceuticals Inc.
- **DATE OF NAME CHANGE:** 20160115

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RestorGenex Corp
- **DATE OF NAME CHANGE:** 20140307

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Stratus Media Group, Inc
- **DATE OF NAME CHANGE:** 20080722

?xml version='1.0' encoding='ASCII'? crvo20251029c_8k.htm

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 8-K**

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

**October 27, 2025**

**Date of Report (Date of earliest event reported)**

------

## CervoMed Inc.
**(Exact name of registrant as specified in its charter)**

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37942** | **30-0645032** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **20 Park Plaza, Suite 424**<br> **Boston, Massachusetts** | **20 Park Plaza, Suite 424**<br> **Boston, Massachusetts** | **02116** |
| **(Address of principal executive offices)** | **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant**'**s telephone number, including area code: (617) 744-4400**

**Not applicable**

**(Former name or former address, if changed since last report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, $0.001 par value | CRVO | NASDAQ Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On October 27, 2025, the Board of Directors (the "Board") of CervoMed Inc. (the "Company") appointed David Quigley as a director of the Company.

Mr. Quigley, age 58, served at the global consulting firm McKinsey & Company ("McKinsey") for more than 25 years, including as Senior Partner from 2010 to 2025. While a Senior Partner at McKinsey, Mr. Quigley at times held various leadership roles including Global Head of Private Capital (Private Equity), North America Head of Life Sciences, and Global Lead of Life Sciences Commercial. He also served as a guest lecturer on Life Sciences at Columbia University's Mailman School of Public Health from 2010 to 2017. Mr. Quigley holds a B.A. from University College Dublin, an M.Sc. from Queen's University Belfast, and an M.B.A. from INSEAD.

In connection with his appointment to the Board, Mr. Quigley was granted a stock option to purchase 16,200 shares of the Company's common stock. The option grant has an exercise price equal to $7.02, the closing price of the Company's common stock on the grant date, will vest in 36 equal monthly installments on the last calendar day of each month commencing October 31, 2025, and will be subject to the other terms and conditions set forth in the Company's 2025 Equity Incentive Plan and its standard form of option award agreement. In addition to the option grant, (i) Mr. Quigley will receive the other cash and equity compensation payable to the Company's non-employee directors pursuant to its non-employee director compensation program (pro-rated as applicable to reflect the actual time Mr. Quigley will serve on the Board for this year) and (ii) effective upon his election to the Board, the Company and Mr. Quigley entered into the Company's standard form of director and officer indemnification agreement.

Effective upon Mr. Quigley's election as a director of the Company, the size of the Board was expanded from seven to eight members and Mr. Quigley will serve for a term to continue until the Company's next annual meeting of stockholders. Mr. Quigley will not serve on any of the Board's standing committees. There are no arrangements or understandings between Mr. Quigley and any other persons pursuant to which Mr. Quigley was selected as a director of the Company and there are also no family relationships between Mr. Quigley and any director or executive officer of the Company.

**Item 7.01**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Regulation FD Disclosure**

On October 28, 2025, the Company issued a press release announcing the appointment of Mr. Quigley as a director. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Financial Statements and Exhibits**

***(d)***&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ***Exhibits***

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release, issued October 28, 2025](ex_878763.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: October 29, 2025 | **CervoMed Inc.** | **CervoMed Inc.** |
|  | By: | /s/ William Elder |
|  | Name: | William Elder |
|  | Title: | Chief Financial Officer & General Counsel |

---

## Exhibit 99.1

**Exhibit 99.1**

**CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley**

*Mr. Quigley most recently led McKinsey & Company*'*s Private Capital practice and previously led various Life Sciences practices at the firm*

*Appointment adds deep business strategy, transactional, and commercial expertise as CervoMed prepares for Phase 3 and commercialization planning*

**BOSTON, October 28, 2025** — CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced the appointment of David Quigley to its Board of Directors (Board). Mr. Quigley is a seasoned executive and former Senior Partner at McKinsey & Company, where he led the firm's Life Sciences and Private Equity practices. His appointment comes as CervoMed prepares for key milestones, including U.S. Food and Drug Administration (FDA) feedback on the design of its planned Phase 3 trial in patients with dementia with Lewy bodies (DLB), expected during the fourth quarter of 2025.

"It is a pleasure to welcome David to our Board," said Joshua Boger, Ph.D., Chair of the CervoMed Board of Directors and founder of Vertex Pharmaceuticals. "His strategic insight and commercial acumen are ideally suited to support CervoMed's mission as we advance neflamapimod toward transformative milestones. We look forward to leveraging his extensive business strategy and financial insights, as well as his broad network of relationships in the pharmaceutical and private equity industries, to drive progress for patients and value for our stockholders."

John Alam, M.D., President and Chief Executive Officer of CervoMed, commented, "David's deep industry knowledge and proven track record supporting successful pipeline and commercial development, partnering, and M&A will be invaluable as we progress our planned Phase 3 program in DLB and evaluate strategic and business development initiatives."

Mr. Quigley added, "I am honored to join CervoMed's Board at such a pivotal and exciting time for the Company. The Phase 2b clinical results are compelling, and I believe neflamapimod has the potential to become a first-in-class treatment in DLB. I look forward to working closely with CervoMed's outstanding team and Board to advance this important program and help unlock its full value for patients and stockholders."

Mr. Quigley's distinguished career at McKinsey & Company across more than 25 years included serving as Senior Partner (2010–2025) and holding leadership roles such as Global Head of Private Capital (Private Equity), North America Head of Life Sciences, and Global Lead of Life Sciences Commercial. He has also been a guest lecturer on Life Sciences at Columbia University's Mailman School of Public Health. Mr. Quigley holds a B.A. from University College Dublin, an M.Sc. from Queen's University Belfast, and an M.B.A. from INSEAD.

------

**About Dementia with Lewy Bodies**

DLB is the second most common progressive dementia after Alzheimer's disease, affecting millions worldwide. Patients may experience a combination of decline in cognitive function, cognitive fluctuations, visual hallucinations, and sleep disorders, as well as motor symptoms similar to Parkinson's disease. There are no approved treatments for DLB in the United States or European Union, and the current standard-of-care therapies only temporarily relieve symptoms.

**About CervoMed**

CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is a small molecule designed to restore communication between brain cells by inhibiting a key enzyme involved in inflammation and neurodegeneration. CervoMed's recently completed, successful Phase 2b RewinD-LB trial evaluated neflamapimod in DLB patients who have a low likelihood of AD co-pathology, and the Company plans to initiate a global Phase 3 trial in the same patient population in mid-2026.

**Forward-Looking Statements**<br> This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to: the therapeutic potential of neflamapimod, including the degree of sustainability of any therapeutic effects; the anticipated timing and achievement of clinical and development milestones, including the Company's announcement of additional data or any meeting or correspondence between the Company and the FDA; any other expected or implied benefits or results, including that any initial clinical results observed with respect to neflamapimod in the RewinD-LB trial will be replicated in later trials; and the timing of the initiation of any potential future trials or interactions with regulatory authorities, including the Company's need to acquire sufficient funding for any Phase 3 trial of neflamapimod in DLB and/or the future approval, if any, of neflamapimod by regulatory authorities for the treatment of DLB or any other indication. Terms such as "believes," "estimates," "anticipates," "expects," "plans," "aims," "seeks," "intends," "may," "might," "could," "might," "will," "should," "approximately," "potential," "target," "project," "contemplate," "predict," "forecast," "continue," or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company's control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company's available cash resources and the availability of additional funds on acceptable terms; the results of the Company's clinical trials, including RewinD-LB; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (SEC) on March 17, 2025, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.

**Contacts**

**Investors:**<br> PJ Kelleher<br> LifeSci Advisors<br> <u>Investors@cervomed.com</u><br> 617-430-7579

**Media:**<br> Argot Partners<br> <u>liza@argotpartners.com</u><br> 212-600-1902